awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37285565-C2A3BCB6-2841-466A-A885-EE4CC132A661
Q37285565-C2A3BCB6-2841-466A-A885-EE4CC132A661
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37285565-C2A3BCB6-2841-466A-A885-EE4CC132A661
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab
P2860
Q37285565-C2A3BCB6-2841-466A-A885-EE4CC132A661
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37285565-C2A3BCB6-2841-466A-A885-EE4CC132A661
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1a6f3cd0e4637719083cfa987eb02004944b19a2
P2860
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption